Latest Stem Cell Exosome Clinical Findings

Exosomes secreted from stem cells have, over the past few years, become one of the most-mentioned keywords in the areas of hair loss, skin regeneration, and anti-aging. It is true that, as very small particles that transmit signals between cell and cell, they are drawing attention as a new tool of regenerative medicine. However, in the clinic, a distance that still must be bridged clearly exists between this expectation and the actual clinical evidence. This article is intended to organize, in a balanced way from an academic viewpoint, how far the research surrounding exosomes has come and how the Ministry of Food and Drug Safety and overseas regulatory agencies view it. To say the conclusion in advance, exosomes are a research field of great potential, not yet an established standard treatment.

Exosomes are extracellular vesicles of several tens to several hundreds of nanometers in diameter secreted by many cells, including stem cells. Within them are contained proteins, lipids, and genetic material such as mRNA and microRNA, so they are known to play a kind of messenger role of exchanging information between cells. In the past, the method of transplanting stem cells themselves was the center of research, but because of the variability and safety problems of using living cells as they are, the so-called concept of cell-free therapy, which utilizes the exosomes that are the products secreted by cells, has emerged.

On the basis of this background, exosomes are being studied in various areas such as hair follicle regeneration, skin collagen production, and tissue recovery. According to a review based on clinical-trial registration data under the U.S. National Institutes of Health, it is reported that numerous exosome-related clinical trials targeting cardiovascular disease, graft-versus-host disease, neurological disease, and others are registered and in progress. That is, while the interest and investment of academia are clearly active, it is also necessary to understand together that most of them are exploratory studies in the early to middle stage.

Hair loss is one of the areas in which exosomes are most actively studied. When the nutrient supply to the hair root drops or the environment around the hair follicle worsens, the hair tends to thin and fall out, and a hypothesis has been raised that mesenchymal stem cell-derived exosomes can stimulate dermal papilla cells, activate hair follicle stem cells, and promote blood vessel formation. In fact, patent applications and preclinical studies dealing with such mechanisms exist, and the mesenchymal stem cell-derived nanovesicle-based hair-growth-promoting composition that the director introduced in a previous article is also on the same flow.

However, the potential observed in preclinical work does not directly guarantee an effect in humans. Looking at a systematic review that synthesizes the clinical evidence in the hair regeneration field, the limitations that the number of included studies is small, randomized controlled studies are limited, and the source, dose, and follow-up period of the exosomes used differ from study to study are repeatedly pointed out. Patient satisfaction is reported as relatively high and serious adverse reactions are rarely reported, but academia's cautious conclusion is that the quality of evidence is not yet sufficiently mature to assert that the effect has been proven.

In the skin area too, exosomes are being studied from the viewpoint that they may have the potential to help collagen and elastin production and calm inflammation, contributing to improving skin texture and elasticity. Review literature dealing with clinical application in the cosmetic dermatology area mentions the potential for exosomes to be used auxiliarily for recovery after laser procedures or for concerns such as fine wrinkles and pigmentation. In this context, exosomes are often considered together with procedures whose evidence is comparatively well established, rather than as a standalone treatment.

In actual care, to those who are troubled by reduced skin elasticity or overall skin aging, rather than pinning expectation on exosomes alone, I first explain harmony with approaches that have more accumulated evidence, such as restoring skin elasticity through collagen regeneration or the principle of combined laser and PRP treatment. Even if you are interested in exosomes, a process of organizing your own skin condition and goals together is needed, and looking first at the principle of stem cell skin care helps.

If a question arises, rather than judging by searching alone, we recommend confirming through care. Consult about exosome-related questions

The most important yet often omitted part when talking about exosomes is the regulatory status. To say the conclusion first, there is as yet no case of approving exosomes as a standardized pharmaceutical treatment, both domestically and abroad. It is reported that the U.S. Food and Drug Administration (FDA), while making clear that there is no formally approved exosome product, has issued a public health warning and numerous warning letters regarding the marketing of unverified stem cell and exosome products.

You may understand the domestic situation in a similar context. The Ministry of Food and Drug Safety, in principle, does not allow human cell and tissue culture fluid to be used as a cosmetic ingredient, but permits it limitedly only in cases that comply with separate safety standards. Regarding exosomes as a pharmaceutical, that is, extracellular vesicle therapeutics, it is at the stage of preparing guidelines on quality and nonclinical and clinical evaluation to support new drug development. To organize, it is as follows.

The message this table tries to convey is simple. Exosomes are an area being carefully refined within the institutional framework, not a treatment whose verification has already finished.

Let us organize a few misunderstandings often encountered in the clinic. In clinical experience, if information is conveyed in only one direction, expectation easily inflates beyond reality.

• Exosomes are not stem cells themselves but the products secreted by cells. If the two concepts are accepted as the same, misunderstanding about effect or safety easily arises.
• The culture-fluid ingredient put into cosmetics and the treatment concept handled at a medical institution are different regulatory categories. The fact that it was used in cosmetics does not become evidence of a treatment effect.
• That potential has been reported in research does not mean that the same result appears in everyone. There may be individual variation in effect and response.
• That side effects are rarely reported and that it is completely safe are different statements. Sufficient consultation and explanation of risks before a procedure are absolutely necessary.

For these reasons, if you are interested in exosomes or stem cell skin care, an accurate evaluation of your own condition comes before advertising copy. For those troubled by hair loss, checking the main causes of female hair loss together becomes a reasonable starting point.

I think there is no need to unconditionally reject exosomes, nor to expect excessively. What is clear is that this field is being actively studied, and that in some areas the potential for auxiliary use is being reported. At the same time, another clear fact is that large-scale, well-designed randomized controlled studies and standardized manufacturing and management criteria are still further needed. An attitude of honestly acknowledging both is, I believe, the most realistic way to protect patients' health and cost.

So I always say the same thing to those who show interest in exosomes. Rather than rushing the decision, compare your goals, your current condition, and even alternatives whose evidence is better established, together. The cost will be guided after consultation, and for any choice, it is good to decide after hearing a sufficient explanation.

Author: Lee Dong-hee Chief Director · Obstetrician-Gynecologist · View staff profile

First published November 18, 2023 · Last reviewed May 30, 2026

References: U.S. Food and Drug Administration FDA Stem Cell and Exosome Product Public Health Warning (2024), Ministry of Food and Drug Safety Extracellular Vesicle Therapeutics Evaluation Guideline and Human Cell-Tissue Culture Fluid Cosmetic Safety Standard (2023), Systematic Review of Clinical Evidence for Exosome Hair Regeneration PubMed (2024)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical examination.